Evidence map›Paper›PMID 31641547›Full record

ArticleJournal of radiosurgery and SBRT2019

Readmission following inpatient stereotactic radiosurgery for brain tumors.

Austin M Tang, Joshua Bakhsheshian, Michelle Lin, Casey A Jarvis, Edith Yuan, Ian A Buchanan, Li Ding, Ben A Strickland, Eric Chang, Gabriel Zada and 2 more

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in Journal of radiosurgery and SBRT, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Austin M TangKeck School of Medicine, University of Southern California, 1975 Zonal Ave, Los Angeles, CA 90033, USA.
Joshua BakhsheshianDepartment of Neurological Surgery, Keck School of Medicine, University of Southern California, 1200 North State Street Suite 3300, Los Angeles, CA 90033, USA.
Michelle LinKeck School of Medicine, University of Southern California, 1975 Zonal Ave, Los Angeles, CA 90033, USA.
Casey A JarvisKeck School of Medicine, University of Southern California, 1975 Zonal Ave, Los Angeles, CA 90033, USA.
Edith YuanKeck School of Medicine, University of Southern California, 1975 Zonal Ave, Los Angeles, CA 90033, USA.
Ian A BuchananDepartment of Neurological Surgery, Keck School of Medicine, University of Southern California, 1200 North State Street Suite 3300, Los Angeles, CA 90033, USA.
Li DingDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California, 2001 North Soto Street, Los Angeles, CA 90032, USA.
Ben A StricklandDepartment of Neurological Surgery, Keck School of Medicine, University of Southern California, 1200 North State Street Suite 3300, Los Angeles, CA 90033, USA.
Eric ChangDepartment of Radiation Oncology, Keck School of Medicine, University of Southern California, 1441 Eastlake Ave, Los Angeles, CA 90033, USA.
Gabriel ZadaDepartment of Neurological Surgery, Keck School of Medicine, University of Southern California, 1200 North State Street Suite 3300, Los Angeles, CA 90033, USA.
William J MackDepartment of Neurological Surgery, Keck School of Medicine, University of Southern California, 1200 North State Street Suite 3300, Los Angeles, CA 90033, USA.
Frank J AttenelloDepartment of Neurological Surgery, Keck School of Medicine, University of Southern California, 1200 North State Street Suite 3300, Los Angeles, CA 90033, USA.
Neurological Surgery · USUniversity of Southern California · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundStereotactic radiosurgery (SRS) is indicated for a spectrum of brain tumors and is often an outpatient procedure, though severe disease may precipitate inpatient treatment. Readmission following inpatient SRS for brain tumors is not well understood.

objectivesTo characterize rate, associative factors, and predictors of SRS readmission.

methodsRetrospective analysis of inpatients treated with SRS for brain neoplasms was conducted (2010-2014 Nationwide Readmissions Database). Diagnoses upon readmission were characterized. Associations with 30-day readmission were identified using multivariate analyses.

resultsOf 2,553 patients undergoing SRS, 390 were readmitted (15.3%) within 30 days. Leading readmission diagnoses were infectious or embolic. Neurological readmissions of intracerebral hemorrhage (2.1%) and cerebral edema (1.5%) were rare. Malignant tumors (OR=1.60, p=0.007) and discharge to facility (OR=1.41, p=0.004) were associated with readmission.

conclusionInpatients receiving SRS for brain tumors have a 15.3% 30-day readmission rate. Neurologic readmissions were rare, underscoring the neurological safety of SRS, even in sick inpatients.

Indexed as

cancerComplicationsneurosurgeryoncologyquality improvement

Identifiers

PMID31641547
PMCPMC6774493
OpenAlexW2992554500

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.